To see the effect of corticosteroids along with standard treatment in Pneumonia

Outcome of early short course corticosteroid therapy in Severe Community Acquired Pneumonia-A Randomized Controlled Trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/09/036799

Enrollment

132

Registered

2021-09-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J159- Unspecified bacterial pneumonia

Interventions

Intervention1: Dexamethasone. : Dexamethasone is given to the the patients with severe community acquired Pneumonia as intervention along with Standard treatment The drug to be used in this interventi

Eligibility

Inclusion criteria

Inclusion criteria: All cases severe pneumonia will be diagnosed by following criteria: i) 2 months to 59 months: WHO criteria for severe pneumonia will be used. ii) 5 to 15 years: Child need to have tachypnea RR >20/min, fever >38 C, SPo2

Exclusion criteria

Exclusion criteria: 1.Prior treatment with corticosteroids in past 3 months 2.Immunological deficiencies state 3.Prexisting liver, kidney or cardiac disease 4.Nosocomial pneumonia 5.Brochiolitis, bronchial asthma, empyema thoracics, persistent or recurrent pneumonia 6.Hemodynamically instability 7.Severe acute malnutrition.

Design outcomes

Primary

Measure	Time frame
To study the effect of dexamethasone therapy to reduce the clinical failure in children aged 2 month to 15 years with severe community acquired pneumonia.Timepoint: Clinical failure in first 72 hours	—

Secondary

Measure	Time frame
Secondary 1.To compare the a. mortality, b. the duration of the hospital stays, c. need for mechanical ventilation, d. readmission rate within one month e. complications of pneumonia between two groups. 2.To assess the severity of inflammation by assessing (ESR, hsCRP, IL-6,Il 8,IL 10,Procalcitonin) at time of admission and day 4 (after the stopping the steroid therapy) or at the time of discharge. Timepoint: To see the inflammatory markers before starting the intervention or placebo and after 72 hours or at time of discharge	—

Measure

Time frame

Secondary 1.To compare the a. mortality, b. the duration of the hospital stays, c. need for mechanical ventilation, d. readmission rate within one month e. complications of pneumonia between two groups. 2.To assess the severity of inflammation by assessing (ESR, hsCRP, IL-6,Il 8,IL 10,Procalcitonin) at time of admission and day 4 (after the stopping the steroid therapy) or at the time of discharge. Timepoint: To see the inflammatory markers before starting the intervention or placebo and after 72 hours or at time of discharge

—

Countries

India

Contacts

Public ContactNiranjan Biswal

Jawarhalal Institute of Postgraduate Medical Education and Research

drnbiswal@yahoo.com9442528402

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 11, 2026